Gene · 10371
SEMA3A: semaphorin 3A
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. SEMA3A: semaphorin 3A. Genes, record 10371. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/10371
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q14563 | Semaphorin-3A | 771 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents117
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 2472 | Q14563 | Espacenet |
| WO 2025234433 A | 2025-11-13 | 3 | Q14563 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 2057 | Q14563 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 11865 | Q14563 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 11866 | Q14563 | Espacenet |
| JP 2025138725 A | 2025-09-25 | 1936 | Q14563 | Espacenet |
| JP 2025138725 A | 2025-09-25 | 2975 | Q14563 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 7657 | Q14563 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 7657 | Q14563 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 2057 | Q14563 | Espacenet |
1 to 10 of 117
See all 117 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,769
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | SEMA3A papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 5 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 4 | 2025 |
| P30CA016087 | Cancer Center Support Grant | 4 | 2025 |
| P30EY001792 | P30 Core Grant for Vision Research | 4 | 2025 |
| P20GM103449 | Vermont Biomedical Research Network-Vermont INBRE | 3 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
| P30CA013330 | Cancer Center Support Grant | 3 | 2025 |
| P30CA091842 | Cancer Center Support Grant | 3 | 2025 |
| P30DK063491 | Diabetes Research Center (DRC) | 3 | 2025 |
| P30ES017885 | Michigan Center on Lifestage Environmental Exposures and Disease (M-LEEaD) | 3 | 2025 |
1 to 10 of 1,769Source NIH's project files
See all 1,769 nih grantsPapers3,028
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Corrigendum to "Decreased expression of Sema3A, an immune modulator, in blood sample of multiple sclerosis patients" [Gene 610 (2017) 59-63]. | Gene | 2026 | 42763226 | PubTator, text mining | PubMed |
| SGLT2 Inhibitors Are Associated With Suppression of the Sema3A/NRP1/Plexin-A1 Signaling Axis in Postmenopausal Women With Type 2 Diabetes: Evidence From Propensity Score-Matched Analysis. | J Diabetes | 2026 | 42649130 | PubTator, text mining | PubMed |
| Targeting Semaphorin-plexin Signaling in Glioblastoma: Implications for Tumor Invasion, Angiogenesis, and Treatment Resistance. | Curr Neurovasc Res | 2026 | 42634324 | PubTator, text mining | PubMed |
| Advances in the study of the role of bone immunity in physiological and pathological processes related to bone metabolism. | Int Immunopharmacol | 2026 | 42546515 | PubTator, text mining | PubMed |
| Differences in immune-related semaphorin levels in the CSF and serum of newly diagnosed, treatment-naive patients with relapsing-remitting multiple sclerosis: a case-control study. | Front Neurol | 2026 | 42524290 | PubTator, text mining | PubMed |
| Evaluation of serum semaphorin-3A and interleukin 6 levels in patients with neovascular age-related macular degeneration. | BMC Ophthalmol | 2026 | 42449255 | PubTator, text mining | PubMed |
| The Role of Sensory and Sympathetic Nerves in the Development and Bone Metabolism of Mandible. | Oral Dis | 2026 | 42438044 | PubTator, text mining | PubMed |
| Semaphorin 3A promotes resilience of sleep and cognition to brain injury. | bioRxiv | 2026 | 42427776 | PubTator, text mining | PubMed |
| Combined HS6ST1 and HS6ST2 loss disrupts the formation and migration of gonadotropin-releasing hormone neurons. | Development | 2026 | 42358159 | PubTator, text mining | PubMed |
| Diverse Roles of Semaphorins on T Cell Activation, Differentiation, Migration, and Effector Functions. | Cells | 2026 | 42346074 | PubTator, text mining | PubMed |
1 to 10 of 3,028
See all 3,028 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/10371
GET https://conductscience.org/api/genes/v1/10371/patents?page=2